Topic: What More We can do on Hepatitis C?

Download All Articles

A special issue of Hepatoma Research  (Print ISSN:2394-5079; Online ISSN:2454-2520).

Deadline for manuscript submissions: 30 Apr 2018

Share This Special Issue

Guest Editor(s)

  • Necati Örmeci, MD
    Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.

    E-mail

Special Issue Introduction:

Hepatitis C virus (HCV) is an enveloped virus with a 9.6 kb single stranded RNA genome. Six HCV genotypes and a large number of subtypes have been identified HCV is an important world-wide health and economic problem through direct and indirect medical cost associated with managing liver disease, decreased work productivity. A hundred eighty million people are infected with HCV in the world. It is thecause of acute hepatitis, chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Besides that, it may results in extra-hepatic manifestations such as mixed cryoglobulinemia, chronic kidney disease, porphyria cutaneatarda, and type 2 diabetes mellitus, rheumatoid-like nondestructive inflammatory arthritis and depression. HCV is associated with the increasing liver related and all causes of mortality.
HCV is one of the important factors (20 % of all causes) for developing the HCC. Almost 700,000 persons died from HCC in a year. HCC is the 6th most common cancer but third common cause of death from the cancer.
Those are the reasons that we made a plan to have a Special Issue about “What More We can do on Hepatitis C?”. It is hoped that this Special Issue will bring novel insights and new solutions to the liver cancer research filed.

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.editorialmanager.com/hres/default.aspx
Submission Deadline: 30 Apr 2018
Contacts: Siqi Li, Assistant Editor, editor001@hrjournal.net

Published Articles Download All Articles
  • HCV elimination: breaking down the barriers to prison based care

    Timothy Papaluca , Alexander Thompson
    Hepatitis C virus (HCV) remains a major public health threat worldwide, responsible for 500,000 deaths annually; hepatocellular carcinoma (HCC) remains one of the major causes of HCV-related mortality. The global prevalence of HCV is approximately 1.0%, and in developed countries, injecting drug use continues to be the primary risk factor in incident cases. Targeted treatment of people who... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:64. | doi:10.20517/2394-5079.2018.53
    Published on: 17 Oct 2018  | Viewed:31  | Downloaded:0
    +HTML| PDF
  • HCV-discovery to elimination, “myth or reality”

    Wasim Jafri , Basit Siddiqui , Safia Awan
    Hepatitis C virus (HCV) was discovered in 1989, before that it was commonly known as transfusion associated non A non B hepatitis. It rapidly assumed the role of leading cause of cirrhosis and liver cancer and a leading indication for liver transplant globally. For over two decades the treatment was suboptimal with the use of pegylated interferon and ribavirin combination across all genotypes.... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:54. | doi:10.20517/2394-5079.2018.36
    Published on: 20 Sep 2018  | Viewed:202  | Downloaded:9
    +HTML| PDF
  • Screening for hepatocellular carcinoma: summary of current guidelines up to 2018

    Nevin Yilmaz , Ugur Eser Yilmaz , Kaya Suer , Vedat Goral , Nedim Cakir
    Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related to worldwide death with a great geographical variation. To be eligible for curative therapy at the time of diagnosis is important. However, the majority of cases are diagnosed at late stages. This can be achieved with applicable screening modalities. Until now, many organizations around the world have developed... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:46. | doi:10.20517/2394-5079.2018.49
    Published on: 16 Aug 2018  | Viewed:566  | Downloaded:40
    +HTML| PDF
  • Elimination of hepatitis from Pakistan by 2030: is it possible?

    Yasir Waheed , Masood Siddiq
    Globally 71 million people are living with hepatitis C virus (HCV) out which 7.1 million (10%) are present in Pakistan. Genotype 3 is the most common HCV type in the country. World Health Organization is working with health authorities in different countries for effective control of HCV, to reduce its incidence by 90% and to reduce hepatitis related mortality by 65% by the year 2030. There are... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:45. | doi:10.20517/2394-5079.2018.58
    Published on: 14 Aug 2018  | Viewed:483  | Downloaded:20
    +HTML| PDF
  • Factors predicting hepatocellular carcinoma in hepatitis C infection

    Zaigham Abbas , Minaam Abbas
    Hepatitis C virus (HCV) has emerged as a leading cause of hepatocellular carcinoma (HCC). In most cases, the virus causes HCC in the presence of chronic hepatic inflammation, advanced fibrosis, and cirrhosis. A combination of viral, environmental, and genetic factors are likely to determine the host immune response to the infection as well as the progression to HCC. Clinical and epidemiologic... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:43. | doi:10.20517/2394-5079.2018.26
    Published on: 8 Aug 2018  | Viewed:299  | Downloaded:21
    +HTML| PDF
  • Heat shock reduces HCV replication via regulation of ribosomal L22 in Alu-RNA molecule dependent manner

    Hamada Farghaly , Adel A. Guirgis , Hany Khalil
    Aim: Hepatitis C virus (HCV) infection is a global health problem that affects more than 180 million people worldwide. HCV is associated with several hepatic and other hepatic disorders including malignancies. HCV is a small enveloped positive-single strand RNA virus that belongs to Hepacivirus in the family Flaviviridae. Here we aim to provide a new therapeutic strategy via treatment of... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:41. | doi:10.20517/2394-5079.2018.30
    Published on: 7 Aug 2018  | Viewed:423  | Downloaded:29
    +HTML| PDF
  • Hepatitis C related hepatocellular carcinoma in the era of direct-acting antivirals

    Akshata Moghe , Obaid S. Shaikh
    Globally, hepatocellular carcinoma (HCC) is the second leading cause of cancer related death. Hepatitis C virus infected patients with cirrhosis or bridging fibrosis are particularly at risk. The risk is reduced among patients who achieve viral clearance with interferon-based regimens. Direct-acting antivirals (DAA) have revolutionized the management of HCV as the treatment is well tolerated,... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:36. | doi:10.20517/2394-5079.2018.54
    Published on: 18 Jul 2018  | Viewed:400  | Downloaded:30
    +HTML| PDF
  • Epidemiology and viral risk factors for hepatocellular carcinoma in the Eastern Mediterranean countries

    Suna Yapali , Nurdan Tozun
    Given the high prevalence of viral hepatitis in the Eastern Mediterranean countries, hepatitis B and C infections are the major causes of hepatocellular carcinoma (HCC) in the region. Most cases are associated with cirrhosis related to hepatitis B or C infection. Environmental, host genetic and viral factors can affect the risk of HCC in patients with hepatitis B and C infection. Understanding... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:24. | doi:10.20517/2394-5079.2018.57
    Published on: 27 Jun 2018  | Viewed:625  | Downloaded:48
    +HTML| PDF
  • Molecular targeting of antiviral drugs used against hepatitis C virus infection

    Mohammad Irshad , Priyanka Gupta , Khushboo Irshad
    Present study reports an update on the molecular interaction of antiviral drugs with viral and host cell components during hepatitis C virus (HCV) infection. In addition to the traditional therapeutic drug regimen, termed as standard of care, some recent drugs have been added in the existing regimen used for HCV infection. These drugs were categorized as direct-acting antivirals (DAAs) agents... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:23. | doi:10.20517/2394-5079.2018.25
    Published on: 26 Jun 2018  | Viewed:332  | Downloaded:22
    +HTML| PDF
  • Ablative techniques in hepatocellular carcinoma treatment

    Ehsun Naeem , Shahab Abid
    Hepatocellular carcinoma has been known to arise commonly in the setting of chronic liver disease. Due to its association with cirrhosis, patients with hepatocellular carcinoma often present with markedly diminished hepatic functional reserve, making them poor surgical candidates. For such patients, image-guided percutaneous ablative modalities have provided a viable alternate curative therapy.... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:18. | doi:10.20517/2394-5079.2018.22
    Published on: 13 Jun 2018  | Viewed:490  | Downloaded:44
    +HTML| PDF
Hepatoma Research ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.